Biotechnology News and Research

RSS

Experimental drug reverses multiple sclerosis damage in mouse model

A drug developed by a UVA Health scientist has not only stopped but reversed paralysis and vision loss in a mouse model of multiple sclerosis.

23 Sep 2026

UVA study evaluates safety and real-world outcomes of histotripsy

UVA Health researchers have reviewed patient outcomes from a new, noninvasive way to treat liver tumors called histotripsy and concluded that while the procedure was associated with low rates of laboratory toxicity and procedural complications, the findings highlight the need to better define which patients are most likely to benefit.

23 Sep 2026

C-Path awards $1.7 million to advance five drug development projects

Critical Path Institute (C-Path) today announced that its Translational Therapeutics Accelerator has awarded $1,699,500 through five Bridging Research and Innovation in Drug Development Grants (BRIDGe).

22 Sep 2026

Galimedix establishes Scientific Advisory Board for Alzheimer’s disease to guide development of novel oral drug candidate, GAL-101

Galimedix Therapeutics, Inc., a Phase 2 clinical-stage biotechnology company developing novel oral and topical neuroprotective therapies with the potential to revolutionize the treatment of serious brain and eye diseases, today announced the establishment of a dedicated Alzheimer's Disease Scientific Advisory Board (SAB).

From Galimedix Therapeutics, INC. 22 Sep 2026

New national guidelines developed to improve sepsis-related care

A UVA Health doctor and other leading national experts have developed important new guidelines to improve care for patients who develop sepsis, a dangerous full-body infection that kills at least 350,000 Americans every year.

18 Sep 2026

Simple fecal test could help detect colorectal and pancreatic cancers

Gastrointestinal and pancreatobiliary cancers can be difficult to detect early, creating a need for practical, noninvasive approaches for early detection and risk assessment.

16 Sep 2026

ACROBiosystems deepens its France presence with a dedicated hub at The HIVE Innovation Center, embedding into the Campus Grand Parc ecosystem

Kadans Science Partner is pleased to welcome ACROBiosystems to The HIVE Innovation Center, its laboratory and office building dedicated to the life sciences, situated on the Campus Grand Parc in Villejuif.

From ACROBiosystems 16 Sep 2026

Harvard scientists design evolutionary traps to stop viral mutations

When a virus mutates, the world usually finds out the hard way. Variants of influenza and SARS‑CoV‑2 can slip past vaccines and antibody drugs before scientists fully understand what has changed.

15 Sep 2026

Aston University partners with Labskin to grow more realistic laboratory-grown human skin

Aston University has joined forces with Yorkshire-based biotechnology company Labskin to develop more realistic laboratory-grown human skin that includes immune cells.

15 Sep 2026

Insilico Medicine launches AI initiative to develop longevity vaccines

Insilico Medicine, a clinical-stage generative artificial intelligence (AI)-driven drug discovery company, today announced Longevity Vaccines, a research initiative developing treatments that direct a patient's own immune cells to eliminate the earliest cellular drivers of age-related disease.

15 Sep 2026

Add-on drug lumateperone boosts sexual function in patients with depression

Patients with major depressive disorder (MDD) and an inadequate response to standard antidepressants who received an add- on treatment with the drug lumateperone saw significantly improved sexual function, found a new study led by a University of Virginia School of Medicine researcher.

15 Sep 2026

Malvern Panalytical launches Zetasizer Core – an industry first in biologics plate-based stability screening

Malvern Panalytical's Zetasizer Core integrates DLS, SLS, and DSF in one platform, streamlining biologics discovery with unmatched efficiency and precision.

From Malvern Panalytical 15 Sep 2026

Laser therapy offers new hope for inoperable pancreatic tumors

UCI Health, the clinical enterprise of the University of California, Irvine, is conducting a first-in-human, phase 1 clinical trial using laser light to target localized but inoperable pancreatic tumors to help patients become cancer free.

10 Sep 2026

Out-of-body experience study yields unexpected results behind closed doors

A test to determine if people who report out-of-body experiences could identify objects in another room produced results no better than chance, but afterward something strange happened: Two participants described, unprompted, researchers' locations and activities behind closed doors.

10 Sep 2026

Review highlights solute carriers as targets for central nervous system disorders

Solute carriers (SLCs) are specialized transport proteins that control the movement of nutrients, ions and neurotransmitters across cell membranes and are essential for brain metabolism and neuronal communication.

10 Sep 2026

Generative AI-driven drug Rentosertib enters Phase III trial for idiopathic pulmonary fibrosis

Insilico Medicine, a clinical-stage biotechnology company powered by generative AI, today announced that it has dosed the first patient with Rentosertib (known as ISM001-055 / INS018_055) in GENESIS-IPF-3, a Phase III clinical trial (NCT07687459, CTR20262475) at Peking Union Medical College Hospital, while Shanghai Pulmonary Hospital has also enrolled its first patient on the same day.

10 Sep 2026

Rentosertib shifts multiple proteomic aging clocks toward younger age profiles in IPF trial

Researchers applied six proteomic aging clocks to serum samples from a phase 2a trial of rentosertib in people with idiopathic pulmonary fibrosis and found treatment-associated shifts toward younger predicted biological-age profiles, particularly with the 30 mg twice-daily regimen. Additional proteomic analyses linked treatment to changes in senescence, metabolism, growth-factor signaling, and fibrosis-related pathways, although the study could not determine whether these effects reflected genuine geroprotection rather than disease modification.

10 Sep 2026

Protein-based MRI agent detects tiny lung cancer metastases

A multi-institutional research team led by Georgia State University Regents' Professor Emerita of Biochemistry and Biophysical Chemistry Jenny J. Yang has developed a new class of protein-based MRI contrast agent that detects invasive lung cancer and metastatic disease at earlier stages than conventional imaging approaches.

9 Sep 2026

EpilepsyGTx and Viralgen collaborate to advance AAV gene therapy program for epilepsy ahead of first-in-human trial

EpilepsyGTx, a biotechnology company developing gene therapies for refractory epilepsy, and Viralgen, a leading contract development and manufacturing organization (CDMO) specializing in recombinant adeno-associated virus (AAV) gene therapies, today announced a partnership to support production of EpilepsyGTx's lead investigational gene therapy program targeting patients with focal refractory epilepsy (FRE), EPY201, ahead of first-in-human clinical trials.

From EpilepsyGTx 9 Sep 2026

OutSee awarded Innovate UK grant for agentic AI pilot study to enhance drug target validation

OutSee, a genomics and drug discovery company pioneering a unique AI-based predictive approach to uncover new drug targets, today announced it has been awarded funding through Innovate UK's Investor Partnership Grant, jointly provided by Innovate UK and Empirical Ventures.

From OutSee 9 Sep 2026

Biotechnology News and Research

Experimental drug reverses multiple sclerosis damage in mouse model

UVA study evaluates safety and real-world outcomes of histotripsy

C-Path awards $1.7 million to advance five drug development projects

Galimedix establishes Scientific Advisory Board for Alzheimer’s disease to guide development of novel oral drug candidate, GAL-101

New national guidelines developed to improve sepsis-related care

Simple fecal test could help detect colorectal and pancreatic cancers

ACROBiosystems deepens its France presence with a dedicated hub at The HIVE Innovation Center, embedding into the Campus Grand Parc ecosystem

Harvard scientists design evolutionary traps to stop viral mutations

Aston University partners with Labskin to grow more realistic laboratory-grown human skin

Insilico Medicine launches AI initiative to develop longevity vaccines

Add-on drug lumateperone boosts sexual function in patients with depression

Malvern Panalytical launches Zetasizer Core – an industry first in biologics plate-based stability screening

Laser therapy offers new hope for inoperable pancreatic tumors

Out-of-body experience study yields unexpected results behind closed doors

Review highlights solute carriers as targets for central nervous system disorders

Generative AI-driven drug Rentosertib enters Phase III trial for idiopathic pulmonary fibrosis

Rentosertib shifts multiple proteomic aging clocks toward younger age profiles in IPF trial

Protein-based MRI agent detects tiny lung cancer metastases

EpilepsyGTx and Viralgen collaborate to advance AAV gene therapy program for epilepsy ahead of first-in-human trial

OutSee awarded Innovate UK grant for agentic AI pilot study to enhance drug target validation

Event guide: 3rd IMPACCT Real World Evidence Summit Europe eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News